| Trial ID: | L7095 |
| Source ID: | NCT01309698
|
| Associated Drug: |
Vildagliptin (Laf237)
|
| Title: |
Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Vildagliptin (LAF237)|DRUG: Voglibose|DRUG: Vildagliptin and Voglibose
|
| Outcome Measures: |
Primary: Pharmacokinetics of vildagliptin, Up to 12 hours post-dose | Secondary: Pharmacodynamic parameters (dipeptidyl peptidase IV (DPP-4) activity, glucagon-like peptide-1(GLP-1), glucose, insulin, glucagon), Up to 4 hours or 12 hours post-dose
|
| Sponsor/Collaborators: |
Sponsor: Novartis Pharmaceuticals
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
24
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2011-02
|
| Completion Date: |
|
| Results First Posted: |
|
| Last Update Posted: |
2020-12-19
|
| Locations: |
Novartis Investigative Site, Tokyo, Japan
|
| URL: |
https://clinicaltrials.gov/show/NCT01309698
|
